AI Article Synopsis
- The study explored the role of tissue transglutaminase (tTG) in human colorectal cancer (CRC) and how cantharidinate affects its expression.* -
- Results revealed that tTG levels were higher in CRC tissues and that cantharidinate effectively inhibited this expression.* -
- The findings suggest that tTG is a key factor in CRC, making it a potential target for cancer prevention and treatment, with cantharidinate as a possible co-therapy.*
Article Abstract
The role of tissue transglutaminase (tTG) in cancer development remains an important field of study. The aim of the current study was to understand the involvement of tTG in cancer and the inhibitory effect of cantharidinate on the expression of tTG in human colorectal cancer (CRC) using immunohistochemical and PCR analysis. The results showed that the expression of tTG increased in human CRC and cantharidinate inhibited the expression of tTG. These results suggested that tTG is significant in human CRC and that tTG may be an important target for tumor chemoprevention and treatment. Cantharidinate may be considered as a novel co‑therapy for controlling tTG expression in human CRC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3892/mmr.2013.1706 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!